A. Monereau, L. Remontet, M. Maynadié, and F. Binder-foucard, Estimation Nationale de l'incidence des Cancers en France entre, 1980.

K. Ekstrom-smedby, Epidemiology and etiology of non-Hodgkin lymphoma ??? a review, Acta Oncologica, vol.23, issue.2, pp.258-71, 2006.
DOI : 10.1016/0277-5379(91)90081-N

J. Fermand, P. Amé-thomas, B. Arnulf, D. Larue, and M. , Mécanismes physiopathologiques des anomalies de la prolifération lymphocytaire, ASSIM, vol.2012

T. Lamy, Avancées dans les Lymphomes Non Hodgkiniens indolents. Les lymphomes folliculaires [Internet]. France lymphome espoir Disponible à : http://www.francelymphomeespoir.fr/medias/Mundipharma-Les-lymphomes-folliculaires.pdf, 2014.

F. Stevenson and G. Stevenson, Follicular lymphoma and the immune system: from pathogenesis to antibody therapy, Blood, vol.119, issue.16, pp.3659-67
DOI : 10.1182/blood-2011-11-367730

H. Rajnai, C. Bödör, Z. Balogh, and E. Gagyi, Impact of the reactive microenvironment on the bone marrow involvement of follicular lymphoma, Histopathology, vol.104, issue.6B, pp.66-75, 2012.
DOI : 10.1073/pnas.0702761104

B. Varet, Lymphomes Non Hodgkiniens Le livre de l'interne Hématologie. Flammarion. Paris: Flammarion, p.579, 2007.

A. Jegalian, F. Eberle, S. Pack, and M. Mirvis, Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma, Blood, vol.118, issue.11, pp.2976-84, 2011.
DOI : 10.1182/blood-2011-05-355255

P. Cong, M. Raffeld, J. Teruya-feldstein, and L. Sorbara, In situ localization of follicular lymphoma: description and analysis by laser capture microdissection, Blood, vol.99, issue.9, pp.3376-82, 2002.
DOI : 10.1182/blood.V99.9.3376

E. Campo, S. Swerdlow, N. Harris, and S. Pileri, The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, issue.19, pp.5019-5051, 2011.
DOI : 10.1182/blood-2011-01-293050

E. Mamessier, F. Broussais-guillaumot, B. Chetaille, and R. Bouabdallah, Nature and importance of follicular lymphoma precursors. Haematologica, Disponible à, pp.802-1005, 2014.

P. Schmidt, P. Cornu, and A. Angelillo-scherrer, Bases physiopathologiques en hématologie générale. Un aide mémoire d'hématologie. Le lymphome folliculaire. Service d'hématologie CHUV-Lausanne, 2013.

H. Horn, C. Schmelter, E. Leich, and I. Salaverria, Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles, Haematologica, vol.96, issue.9, 2011.
DOI : 10.3324/haematol.2011.042531

T. Saati, S. Galoin, R. D. Huynh, and A. , Détection de la maladie résiduelle dans les lymphomes folliculaires par la technique de PCR : intérêt des sondes clono-spécifiques, Bull Cancer Nov, vol.1285, issue.10, pp.847-54, 1998.

C. Sørensen, J. Jørgensen, L. Nederby, and P. Hokland, Common consensus LNA probe for quantitative PCR assays in cancer: Vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas, Journal of Immunological Methods, vol.406, 2014.
DOI : 10.1016/j.jim.2014.03.004

M. Ladetto, C. Lobetti-bodoni, B. Mantoan, and M. Ceccarelli, Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program, Blood, vol.122, issue.23, pp.3759-66, 2013.
DOI : 10.1182/blood-2013-06-507319

M. Juweid, S. Stroobants, O. Hoekstra, and F. Mottaghy, Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.571-579, 2007.
DOI : 10.1200/JCO.2006.08.2305

A. Gallamini and A. Borra, Role of PET in Lymphoma Disponible à : http, Curr Treat Options Oncol, 2014.

C. Tychyj-pinel, R. F. Fulham, M. Fournier, and M. , PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study, European Journal of Nuclear Medicine and Molecular Imaging, vol.71, issue.3, pp.408-423, 2014.
DOI : 10.1016/j.ijrobp.2007.09.051

URL : https://hal.archives-ouvertes.fr/hal-01141154

S. Luminari, I. Biasoli, A. Versari, and S. Rattotti, The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL), Annals of Oncology, vol.101, issue.2, pp.442-449, 2014.
DOI : 10.1182/blood-2002-09-2778

A. Bouché, C. Lize, D. Ranchère-vince, . Lymphome, and . Anabible, Laboratoire d'anatomie pathologique [Internet], 2009.

G. Salles, Clinical features, prognosis and treatment of follicular lymphoma. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program, pp.216-241, 2007.

H. Aamot, E. Torlakovic, M. Eide, and H. Holte, Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic???pathologic???clinical correlations, Journal of Cancer Research and Clinical Oncology, vol.316, issue.7, pp.455-70, 2007.
DOI : 10.1016/S0002-9440(10)63284-1

O. Shea, D. O-'riain, C. Taylor, C. Waters, and R. , The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival, Blood, vol.112, issue.8, pp.3126-3135, 2008.
DOI : 10.1182/blood-2008-05-154013

E. Leich, G. Ott, and A. Rosenwald, Pathology, pathogenesis and molecular genetics of follicular NHL, Best Practice & Research Clinical Haematology, vol.24, issue.2, pp.95-109, 2011.
DOI : 10.1016/j.beha.2011.02.003

M. Eide, K. Liestøl, O. Lingjaerde, and M. Hystad, Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones, Blood, vol.116, issue.9, pp.1489-97, 2010.
DOI : 10.1182/blood-2010-03-272278

S. Dave, G. Wright, B. Tan, and A. Rosenwald, Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells, New England Journal of Medicine, vol.351, issue.21, pp.2159-69, 2004.
DOI : 10.1056/NEJMoa041869

J. Carreras, A. Lopez-guillermo, B. Fox, and L. Colomo, High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma, Blood, vol.108, issue.9, pp.2957-64, 2006.
DOI : 10.1182/blood-2006-04-018218

A. Lee, A. Clear, M. Calaminici, and A. Davies, Cells and Location of Forkhead Box Protein P3???Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome, Journal of Clinical Oncology, vol.24, issue.31, pp.5052-5061, 2006.
DOI : 10.1200/JCO.2006.06.4642

A. Glas, M. Kersten, L. Delahaye, and A. Witteveen, Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment, Blood, vol.105, issue.1, pp.301-308, 2005.
DOI : 10.1182/blood-2004-06-2298

B. Wahlin, M. Aggarwal, S. Montes-moreno, and L. Gonzalez, A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1-Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages, Clinical Cancer Research, vol.16, issue.2, pp.637-50, 2010.
DOI : 10.1158/1078-0432.CCR-09-2487

B. Wahlin, B. Sander, B. Christensson, and E. Kimby, CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res, pp.388-97, 2007.

A. Clear, A. Lee, M. Calaminici, and A. Ramsay, Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment, Blood, vol.115, issue.24, pp.5053-5059, 2010.
DOI : 10.1182/blood-2009-11-253260

J. Michels, V. Foria, B. Mead, and G. Jackson, Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma, British Journal of Haematology, vol.90, issue.6, pp.743-749, 2006.
DOI : 10.1182/blood.V97.12.3902

W. Zhao, M. Daneshpouy, N. Mounier, and J. Brière, Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood, pp.695-702, 2004.

Y. Li, H. Nagai, T. Ohno, and M. Yuge, Aberrant DNA methylation of p57KIP2 gene in the promoter region in lymphoid malignancies of B-cell phenotype, Blood, vol.100, issue.7, pp.2572-2579, 2002.
DOI : 10.1182/blood-2001-11-0026

D. Rossi, D. Capello, A. Gloghini, and S. Franceschetti, Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia, Haematologica, 2004.

M. Giachelia, V. Bozzoli, D. Alò, F. Tisi, and M. , Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker, The Journal of Molecular Diagnostics, vol.16, issue.4, 2009.
DOI : 10.1016/j.jmoldx.2014.03.003

K. Ardeshna, P. Smith, A. Norton, and B. Hancock, Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial, The Lancet, vol.362, issue.9383, pp.516-538, 2003.
DOI : 10.1016/S0140-6736(03)14110-4

M. Ghielmini, U. Vitolo, E. Kimby, and S. Montoto, ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), Annals of Oncology, vol.94, issue.5, pp.561-76, 2013.
DOI : 10.3324/haematol.2008.000273

K. Ardeshna, W. Qian, P. Smith, and N. Braganca, Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial, The Lancet Oncology, vol.15, issue.4, pp.424-3505, 2014.
DOI : 10.1016/S1470-2045(14)70027-0

R. Haas, P. Poortmans, D. De-jong, and B. Aleman, High Response Rates and Lasting Remissions After Low-Dose Involved Field Radiotherapy in Indolent Lymphomas, Journal of Clinical Oncology, vol.21, issue.13, pp.2474-80, 2003.
DOI : 10.1200/JCO.2003.09.542

P. Hoskin, A. Kirkwood, B. Popova, and P. Smith, 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial, The Lancet Oncology, vol.15, issue.4, 2014.
DOI : 10.1016/S1470-2045(14)70036-1

R. Fisher, M. Leblanc, O. Press, and D. Maloney, New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma, Journal of Clinical Oncology, vol.23, issue.33, pp.8447-52, 2005.
DOI : 10.1200/JCO.2005.03.1674

A. Freedman and . Follicular-lymphoma, Follicular lymphoma: 2014 update on diagnosis and management, American Journal of Hematology, vol.115, issue.4, pp.429-465, 2014.
DOI : 10.1182/blood-2009-08-236471

R. Marcus, K. Imrie, P. Solal-celigny, and J. Catalano, Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.28, pp.4579-86, 2008.
DOI : 10.1200/JCO.2007.13.5376

W. Hiddemann, M. Kneba, M. Dreyling, and N. Schmitz, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood, vol.106, issue.12, pp.3725-3757, 2005.
DOI : 10.1182/blood-2005-01-0016

M. Herold, A. Haas, S. Srock, and S. Neser, Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study, Journal of Clinical Oncology, vol.25, issue.15, pp.1986-92, 2007.
DOI : 10.1200/JCO.2006.06.4618

G. Salles, N. Mounier, and S. De-guibert, Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study, Blood, vol.112, issue.13, pp.4824-4855, 2008.
DOI : 10.1182/blood-2008-04-153189

G. Salles and H. Ghesquières, Current and future management of follicular lymphoma, International Journal of Hematology, vol.24, issue.2, pp.544-51, 2012.
DOI : 10.1016/j.beha.2011.03.006

J. Dupuis, A. Berriolo-riedinger, and A. Julian, Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS, J Clin Oncol Dec, vol.1030, issue.3506, pp.4317-4339, 2012.

M. Rummel, N. Niederle, G. Maschmeyer, and G. Banat, Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial, The Lancet, vol.381, issue.9873, pp.1203-1213, 2013.
DOI : 10.1016/S0140-6736(12)61763-2

T. Watanabe, K. Tobinai, T. Shibata, and K. Tsukasaki, Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial, Journal of Clinical Oncology, vol.29, issue.30, pp.3990-3998, 2011.
DOI : 10.1200/JCO.2011.34.8508

P. Colombat and . Rituximab, Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation, Blood, vol.97, issue.1, pp.101-107, 2001.
DOI : 10.1182/blood.V97.1.101

G. Martinelli, S. Schmitz, U. Utiger, and T. Cerny, Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98, Journal of Clinical Oncology, vol.28, issue.29, pp.4480-4484, 2010.
DOI : 10.1200/JCO.2010.28.4786

C. Bodet-milin, A. Oudoux, and F. Kraeber-bodéré, La radio-immunothérapie. Médecine Nucl, Consulté le 03, pp.148-51, 2009.

C. Scholz, A. Pinto, W. Linkesch, and O. Lindén, Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial, Journal of Clinical Oncology, vol.31, issue.3, pp.308-321, 2013.
DOI : 10.1200/JCO.2011.41.1553

F. Morschhauser, J. Radford, A. Van-hoof, and B. Botto, Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial, Journal of Clinical Oncology, vol.31, issue.16, pp.311977-83, 2013.
DOI : 10.1200/JCO.2012.45.6400

. Roche, Résumé des caractéristiques du produit. Mabthera (Rituximab) [Internet]. Agence européenne des médicaments, 2014.

D. Maloney, Anti-CD20 Antibody Therapy for B-Cell Lymphomas, New England Journal of Medicine, vol.366, issue.21, pp.2008-2024, 2012.
DOI : 10.1056/NEJMct1114348

P. Boross and J. Hw-leusen, Mechanisms of action of cd20 antibodies, Am J Cancer Res, vol.2, issue.6, pp.676-90, 2012.

A. Rezvani and D. Maloney, Rituximab resistance, Best Practice & Research Clinical Haematology, vol.24, issue.2, 2011.
DOI : 10.1016/j.beha.2011.02.009

G. Salles, J. Seymour, F. Offner, and A. López-guillermo, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, The Lancet, vol.377, issue.9759, pp.42-51, 2011.
DOI : 10.1016/S0140-6736(10)62175-7

K. Takei, T. Yamazaki, U. Sawada, and H. Ishizuka, Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines, Leukemia Research, vol.30, issue.5, 2006.
DOI : 10.1016/j.leukres.2005.09.008

J. Golay, M. Lazzari, V. Facchinetti, and S. Bernasconi, CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59, Blood, vol.98, issue.12, pp.3383-3392, 2001.
DOI : 10.1182/blood.V98.12.3383

A. Jazirehi, M. Vega, and B. Bonavida, Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res, Feb, vol.167, issue.306, pp.1270-81, 2007.

J. Hainsworth, S. Litchy, H. Burris, and D. Scullin, Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin???s Lymphoma, Journal of Clinical Oncology, vol.20, issue.20, pp.4261-4268, 2002.
DOI : 10.1200/JCO.2002.08.674

J. Hainsworth, S. Litchy, D. Shaffer, and V. Lackey, Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma???A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network, Journal of Clinical Oncology, vol.23, issue.6
DOI : 10.1200/JCO.2005.12.191

M. Ghielmini, S. Schmitz, S. Cogliatti, and G. Pichert, Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule, Blood, vol.103, issue.12, pp.4416-4439, 2004.
DOI : 10.1182/blood-2003-10-3411

R. Forstpointner, M. Unterhalt, M. Dreyling, and H. Böck, Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG), Blood, vol.108, issue.13, pp.4003-4011, 2006.
DOI : 10.1182/blood-2006-04-016725

M. Van-oers, R. Klasa, R. Marcus, and M. Wolf, Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial, Blood, vol.108, issue.10, pp.3295-301, 2006.
DOI : 10.1182/blood-2006-05-021113

H. Hochster, E. Weller, R. Gascoyne, and T. Habermann, Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study, Journal of Clinical Oncology, vol.27, issue.10, pp.1607-1621, 2009.
DOI : 10.1200/JCO.2008.17.1561

J. Greenhalgh, A. Bagust, A. Boland, and M. Blundell, Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin???s Lymphoma, Disponible à, pp.403-416, 2013.
DOI : 10.3109/10428194.2011.628061

H. Blommestein, D. Issa, M. Pompen, T. Hoor, and G. , Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study, European Journal of Haematology, vol.47, issue.5, pp.398-406, 2014.
DOI : 10.1080/02841860802120028

A. Salar, I. Avivi, B. Bittner, and R. Bouabdallah, Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study, Journal of Clinical Oncology, vol.32, issue.17, pp.1782-91, 2014.
DOI : 10.1200/JCO.2013.52.2631

A. Davies, F. Merli, B. Mihaljevic, and N. Siritanaratkul, Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study, The Lancet Oncology, vol.15, issue.3, pp.343-52, 2014.
DOI : 10.1016/S1470-2045(14)70005-1

H. Kluin-nelemans, E. Hoster, O. Hermine, and J. Walewski, Treatment of Older Patients with Mantle-Cell Lymphoma, New England Journal of Medicine, vol.367, issue.6, pp.520-551, 2009.
DOI : 10.1056/NEJMoa1200920

B. Kahl, F. Hong, M. Williams, and R. Gascoyne, Rituximab extended schedule or retreatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402, J Clin Oncol Off J Am Soc Clin Oncol Oct, vol.1, issue.3228, pp.3096-102, 2014.